Neurocrine Biosciences To Report Impact Of Classical Congenital Adrenal Hyperplasia At Endocrine Nurses Society Annual Symposium 2026
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new real-world data demonstrating how the clinical and day-to-day impact of classic congenital adrenal hyperplasia can vary among individuals and evolve
Neurocrine is sharing new real-world information about a rare hormone condition. Watch to see if doctors find their treatment helps patients feel better in daily life.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.